LabCorp also entered into a lab services relationship with the healthcare system, through which it will provide reference testing for all the system's facilities and clinics.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
The company reported $2.77 billion in revenues on the quarter, down from $2.88 billion in Q2 2019 but above the consensus Wall Street estimate of $2.5 billion.
The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.
